Movement Alert｜Hengrui Medicine Rises 3.02% in Regular Trading, Multiple Drug Approvals and Institutional Buying Boost Sentiment

Market Focus06-18

On June 18, Hengrui Medicine rose 3.02% in regular trading, trading at 54.7 HKD/share, with turnover of approximately 46.74 million HKD. The rally was driven by a convergence of positive catalysts including new drug approvals, clinical trial advancements, and institutional accumulation.

On the regulatory front, NMPA approved a new indication for Hengrui's dalpiciclib isethionate tablets (a CDK4/6 inhibitor) for early-stage breast cancer with high recurrence risk. Separately, HRS-7525 tablets and SHR-6914 injection both received clinical trial approvals for solid tumors and prostate cancer-related tumors, respectively, further expanding the company's oncology pipeline.

On the capital side, Schroders increased its stake by approximately 948,800 shares on June 12 at around 54.54 HKD per share, lifting its holding from 4.75% to 5.11%. Meanwhile, management continued its A-share buyback program, repurchasing 120,000 shares on June 17 at approximately RMB 46.85–46.88 per share, spending roughly RMB 5.62 million, signaling confidence in the company's intrinsic value.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142436116?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 10:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142436116","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Hengrui Medicine Rises 3.02% in Regular Trading, Multiple Drug Approvals and Institutional Buying Boost Sentiment","media":"Market Focus","content":"<p><p>On June 18, Hengrui Medicine rose 3.02% in regular trading, trading at 54.7 HKD/share, with turnover of approximately 46.74 million HKD. The rally was driven by a convergence of positive catalysts including new drug approvals, clinical trial advancements, and institutional accumulation.</p><p>On the regulatory front, NMPA approved a new indication for Hengrui's dalpiciclib isethionate tablets (a CDK4/6 inhibitor) for early-stage breast cancer with high recurrence risk. Separately, HRS-7525 tablets and SHR-6914 injection both received clinical trial approvals for solid tumors and prostate cancer-related tumors, respectively, further expanding the company's oncology pipeline.</p><p>On the capital side, Schroders increased its stake by approximately 948,800 shares on June 12 at around 54.54 HKD per share, lifting its holding from 4.75% to 5.11%. Meanwhile, management continued its A-share buyback program, repurchasing 120,000 shares on June 17 at approximately RMB 46.85–46.88 per share, spending roughly RMB 5.62 million, signaling confidence in the company's intrinsic value.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hengrui Medicine Rises 3.02% in Regular Trading, Multiple Drug Approvals and Institutional Buying Boost Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hengrui Medicine Rises 3.02% in Regular Trading, Multiple Drug Approvals and Institutional Buying Boost Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-18 10:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 18, Hengrui Medicine rose 3.02% in regular trading, trading at 54.7 HKD/share, with turnover of approximately 46.74 million HKD. The rally was driven by a convergence of positive catalysts including new drug approvals, clinical trial advancements, and institutional accumulation.</p><p>On the regulatory front, NMPA approved a new indication for Hengrui's dalpiciclib isethionate tablets (a CDK4/6 inhibitor) for early-stage breast cancer with high recurrence risk. Separately, HRS-7525 tablets and SHR-6914 injection both received clinical trial approvals for solid tumors and prostate cancer-related tumors, respectively, further expanding the company's oncology pipeline.</p><p>On the capital side, Schroders increased its stake by approximately 948,800 shares on June 12 at around 54.54 HKD per share, lifting its holding from 4.75% to 5.11%. Meanwhile, management continued its A-share buyback program, repurchasing 120,000 shares on June 17 at approximately RMB 46.85–46.88 per share, spending roughly RMB 5.62 million, signaling confidence in the company's intrinsic value.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1142436116","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142436116","pubTimestamp":1781749437,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 18, Hengrui Medicine rose 3.02% in regular trading, trading at 54.7 HKD/share, with turnover of approximately 46.74 million HKD. The rally was driven by a convergence of positive catalysts...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"运动快讯|恒瑞医药常规交易涨3.02%多个药品获批机构买盘提振情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"On June 18, Hengrui Medicine rose 3.02% in regular trading, trading at 54.7 HKD/share, with turnover of approximately 46.74 million HKD. The rally was driven by a convergence of positive catalysts including new drug approvals, clinical trial advancements, and institutional accumulation.On the regulatory front, NMPA approved a new indication for Hengrui's dalpiciclib isethionate tablets (a CDK4/6 inhibitor) for early-stage breast cancer with high recurrence risk. Separately, HRS-7525 tablets and SHR-6914 injection both received clinical trial approvals for solid tumors and prostate cancer-related tumors, respectively, further expanding the company's oncology pipeline.On the capital side, Schroders increased its stake by approximately 948,800 shares on June 12 at around 54.54 HKD per share, lifting its holding from 4.75% to 5.11%. Meanwhile, management continued its A-share buyback program, repurchasing 120,000 shares on June 17 at approximately RMB 46.85–46.88 per share, spending roughly RMB 5.62 million, signaling confidence in the company's intrinsic value.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142436116","isCrawlerRequest":true}